Plc Astrazeneca - Net Worth and Insider Trading
Plc Astrazeneca Net Worth
The estimated net worth of Plc Astrazeneca is at least $804 Million dollars as of 2024-12-28. Plc Astrazeneca is the 10% Owner of Viela Bio Inc and owns about 14,650,334 shares of Viela Bio Inc (VIE) stock worth over $777 Million. Plc Astrazeneca is the 10% Owner of Albireo Pharma Inc and owns about 508,141 shares of Albireo Pharma Inc (ALBO) stock worth over $22 Million. Plc Astrazeneca is also the 10% Owner of Entasis Therapeutics Holdings Inc and owns about 2,164,855 shares of Entasis Therapeutics Holdings Inc (ETTX) stock worth over $5 Million. Besides these, Plc Astrazeneca also holds Regulus Therapeutics Inc (RGLS) , PhaseBio Pharmaceuticals Inc (PHASQ) . Details can be seen in Plc Astrazeneca's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Plc Astrazeneca has not made any transactions after 2019-10-07 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Plc Astrazeneca
Plc Astrazeneca Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Plc Astrazeneca owns 6 companies in total, including Aevi Genomic Medicine Inc (GNMX) , Viela Bio Inc (VIE) , and PhaseBio Pharmaceuticals Inc (PHASQ) among others .
Click here to see the complete history of Plc Astrazeneca’s form 4 insider trades.
Insider Ownership Summary of Plc Astrazeneca
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| GNMX | Aevi Genomic Medicine Inc | 2019-12-19 | 10 percent owner |
| VIE | Viela Bio Inc | 2019-10-07 | 10 percent owner |
| PHASQ | PhaseBio Pharmaceuticals Inc | 2018-10-22 | 10 percent owner |
 | | 2018-09-28 | 10 percent owner |
| | 2017-12-01 | 10 percent owner |
| | 2012-10-10 | 10 percent owner |
Plc Astrazeneca Latest Holdings Summary
Plc Astrazeneca currently owns a total of 5 stocks. Among these stocks, Plc Astrazeneca owns 14,650,334 shares of Viela Bio Inc (VIE) as of October 7, 2019, with a value of $777 Million and a weighting of 96.61%. Plc Astrazeneca owns 508,141 shares of Albireo Pharma Inc (ALBO) as of December 1, 2017, with a value of $22 Million and a weighting of 2.79%. Plc Astrazeneca also owns 2,164,855 shares of Entasis Therapeutics Holdings Inc (ETTX) as of September 28, 2018, with a value of $5 Million and a weighting of 0.59%. The other 2 stocks Regulus Therapeutics Inc (RGLS) , PhaseBio Pharmaceuticals Inc (PHASQ) have a combined weighting of 0.01% among all his current holdings.
Latest Holdings of Plc Astrazeneca
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| VIE | Viela Bio Inc | 2019-10-07 | 14,650,334 | 53.01 | 776,614,205 |
| ALBO | Albireo Pharma Inc | 2017-12-01 | 508,141 | 44.15 | 22,434,425 |
| ETTX | Entasis Therapeutics Holdings Inc | 2018-09-28 | 2,164,855 | 2.19 | 4,741,032 |
| RGLS | Regulus Therapeutics Inc | 2012-10-10 | 52,083 | 1.54 | 80,208 |
| PHASQ | PhaseBio Pharmaceuticals Inc | 2018-10-22 | 3,004,554 | 0.00 | 300 |
Holding Weightings of Plc Astrazeneca
Plc Astrazeneca Form 4 Trading Tracker
According to the SEC Form 4 filings, Plc Astrazeneca has made a total of 0 transactions in Viela Bio Inc (VIE) over the past 5 years. The most-recent trade in Viela Bio Inc is the acquisition of 425,000 shares on October 7, 2019, which cost Plc Astrazeneca around $8 Million.
According to the SEC Form 4 filings, Plc Astrazeneca has made a total of 0 transactions in Albireo Pharma Inc (ALBO) over the past 5 years. The most-recent trade in Albireo Pharma Inc is the sale of 500,000 shares on December 1, 2017, which brought Plc Astrazeneca around $11 Million.
According to the SEC Form 4 filings, Plc Astrazeneca has made a total of 0 transactions in Entasis Therapeutics Holdings Inc (ETTX) over the past 5 years. The most-recent trade in Entasis Therapeutics Holdings Inc is the acquisition of 246,666 shares on September 28, 2018, which cost Plc Astrazeneca around $4 Million.
More details on Plc Astrazeneca's insider transactions can be found in the Insider Trading History of Plc Astrazeneca table.Insider Trading History of Plc Astrazeneca
- 1
Plc Astrazeneca Trading Performance
GuruFocus tracks the stock performance after each of Plc Astrazeneca's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Plc Astrazeneca is -19.65%. GuruFocus also compares Plc Astrazeneca's trading performance to market benchmark return within the same time period. The performance of stocks bought by Plc Astrazeneca within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Plc Astrazeneca's insider trading performs compared to the benchmark.
Performance of Plc Astrazeneca
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -21.85 | | | | | |
| Relative Return to S&P 500(%) | -19.31 | | | | | |
Plc Astrazeneca Ownership Network
Plc Astrazeneca Owned Company Details
What does Aevi Genomic Medicine Inc do?
Who are the key executives at Aevi Genomic Medicine Inc?
Plc Astrazeneca is the 10 percent owner of Aevi Genomic Medicine Inc. Other key executives at Aevi Genomic Medicine Inc include director & Chief Executive Officer Michael F Cola , Chief Scientific Officer Garry Arthur Neil , and CFO & Corporate Secretary Brian Piper .
Aevi Genomic Medicine Inc (GNMX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Aevi Genomic Medicine Inc (GNMX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aevi Genomic Medicine Inc (GNMX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Aevi Genomic Medicine Inc (GNMX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aevi Genomic Medicine Inc Insider Transactions
Plc Astrazeneca Mailing Address
Above is the net worth, insider trading, and ownership report for Plc Astrazeneca. You might contact Plc Astrazeneca via mailing address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge X0 Cb2 0aa.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
